Related Experiment Video
Updated: Jul 20, 2026

High-throughput Quantitative Real-time RT-PCR Assay for Determining Expression Profiles of Types I and III Interferon Subtypes
Published on: March 24, 2015
Drug Insight: interferon treatment in multiple sclerosis
Ruth Ann Marrie1, Richard A Rudick
1Mellen Center for Multiple Sclerosis Treatment and Research, Cleveland Clinic Foundation, Cleveland, OH 44195, USA. marrier@ccf.org
Interferon-beta treatments offer modest benefits for multiple sclerosis (MS) relapses and short-term disability, with greater effects on MRI lesions. Long-term impact on disability progression remains uncertain, highlighting the need for new MS therapies.
Area of Science:
- Neuroimmunology
- Neurology
- Clinical Therapeutics
Background:
- Multiple sclerosis (MS) is a chronic central nervous system demyelinating disease.
- The introduction of recombinant interferon-beta preparations marked a new therapeutic era for MS patients.
- These medications demonstrated safety and efficacy, representing a significant advancement in MS management.
Purpose of the Study:
- To evaluate the benefits and safety of three recombinant interferon-beta formulations in multiple sclerosis patients.
- To assess the impact of interferon-beta on clinical relapses, disability progression, and MRI parameters.
- To explore the differential effects of interferon-beta in various MS subtypes.
Main Methods:
- Clinical trials involving patients with multiple sclerosis between 1987 and 1997.
- Administration of three different recombinant interferon-beta formulations.
- Assessment of clinical outcomes including relapses and disability progression, alongside MRI lesion parameters.
Main Results:
- Interferon-beta formulations showed modest effects on relapses and short-term disability progression.
- More substantial effects were observed on MRI lesion parameters.
- Benefits were more pronounced in clinically isolated syndromes and relapsing-remitting MS compared to secondary progressive MS.
Conclusions:
- Recombinant interferon-beta represents an important advance in multiple sclerosis treatment, offering demonstrable benefits.
- The long-term impact on clinically relevant disability progression is uncertain, and controversies regarding its use persist.
- There remains a need for more effective treatments, potentially involving novel agents or combination therapies for MS.
More Related Videos
08:26Development and Validation of an Ultrasensitive Single Molecule Array Digital Enzyme-linked Immunosorbent Assay for Human Interferon-α
Published on: June 14, 2018
09:38Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination
Published on: September 12, 2016
Related Concept Videos
Inhibitors of Viral Protein Synthesis
Multiple Sclerosis l: Introduction
Antiviral Nucleoside Inhibitors
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
siRNA - Small Interfering RNAs
In the cytoplasm, siRNA is processed from a double-stranded RNA, which comes from either endogenous DNA transcription or exogenous sources like a virus. This double-stranded RNA is then cleaved by the ATP-dependent...
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF